Eisai Opts In On Biogen's High-Profile Aducanumab

 
• By Jessica Merrill

Biogen secures stronger economics for the Phase III Alzheimer's disease drug in the US and Europe in the joint development/commercialization agreement; Eisai picked up rights to Biogen's MS portfolio in Japan and other Asian markets.

Human brain illustrated with millions of small nerves - Conceptual 3d render

More from Business

More from Scrip